Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-08-23
2011-12-06
Kemmerer, Elizabeth C (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008800, C514S016500, C514S021600
Reexamination Certificate
active
08071538
ABSTRACT:
The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
REFERENCES:
patent: 6284882 (2001-09-01), Wu-Wong et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 7511012 (2009-03-01), Han et al.
patent: 7655764 (2010-02-01), Gegg et al.
patent: 7655765 (2010-02-01), Gegg et al.
patent: 7662931 (2010-02-01), Gegg et al.
patent: 2003/0140356 (2003-07-01), Bass et al.
patent: 2004/0087778 (2004-05-01), Feige et al.
patent: 2006/0140934 (2006-06-01), Gegg et al.
patent: 2 333 706 (1999-08-01), None
patent: WO 93/06843 (1993-04-01), None
patent: WO 99/02667 (1999-01-01), None
patent: WO 99/56768 (1999-11-01), None
patent: WO 00/07038 (2000-02-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 00/77206 (2000-12-01), None
patent: WO 01/53350 (2001-07-01), None
patent: WO 02/09641 (2002-02-01), None
Grimm et al., 2011, Nutrition Reviews 69:52-60.
Bradley et al., 2008, Cell. Mol. Life Sci. 65:2119-2124.
McPherron, 2010, Immunol. Endocr. Metab. Agents Med. Chem. 10:217-231.
Dedman et al., “Selection of Targeted Biological Modifiers from a Bacteriophage Library of Random Peptides,”J Biol Chem268(31):23025-23030, 1993.
Hill et al., “The Myostatin Propeptide and the Follistatin-related Gene are Inhibitory Binding Proteins of Myostatin in Normal Serum,”J Biol Chem277(43):40735-40741, 2002.
Lee et al., “Regulation of myostatin activity and muscle growth,”Proc Natl Acad Sci USA98:9306-9311, 2001.
McPherron et al., “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,”Nature387:83-90, 1997.
McPherron and Lee, “Double muscling in cattle due to mutations in the myostatin gene,”Proc Natl Acad Sci USA94:12457-12461, 1997.
Ngo et al, 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand, eds., Birkhauser, Boston, pp. 491-495.
Thies et al., “GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding,”Growth Factors18(4):251-259, 2001.
Wells, “Additivity of Mutational Effects in Proteins,”Biochemistry29(37):8509-8517, 1990.
Zachwieja et al., “Plasma Myostatin-Immunoreactive Protein is Increased After Prolonged Bed Rest With Low-Dose T, Administration,”J Gravitational Physiology6(2):11-15, 1999.
Zimmers et al., “Induction of Cachexia in Mice by Systemically Administered Myostatin,”Science296:1486-1488, 2002.
Boone Thomas C.
Han Hq
Min Hosung
Amgen Inc.
Bellas Christine M.
Hehman Mary K.
Kemmerer Elizabeth C
LandOfFree
Method of increasing muscle mass by administering a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of increasing muscle mass by administering a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of increasing muscle mass by administering a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301533